What this is
- How it works
- How it works isn't classified yet
- Tested for
- Hemophilia B
- Main trialPhase 1/2
- “The purpose of this study is to evaluate the safety of single ascending IV doses of a Factor IX (FIX) Gene Therapy in up to 16 Adults with Hemophilia B.”In the company’s words, NCT01687608 on ClinicalTrials.gov
- Other names
- BAX 335
Other drugs for Hemophilia B
- SR604Shanghai RAAS Blood Products Co., Ltd. · Phase 3
- MARSTACIMABPfizer · Phase 3
- PF-06838435Pfizer · Phase 3
- LNP1265Regeneron · Phase 1/2
- REGV131Regeneron · Phase 1/2
- SR604Equilibra Bioscience LLC · Phase 1
Coming up1
- 17 Jan 2030Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Active, not recruiting | 17 Jan 2030 | Open-Label Single Ascending Dose of Adeno-associated Virus Serotype 8 Factor IX Gene Therapy in Adults With Hemophilia B |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026